New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics
October 04 2023 - 8:30AM
New York Blood Center Enterprises (NYBCe) and Talaris Therapeutics,
Inc. (Nasdaq: TALS) (“Talaris”) announced today NYBCe’s acquisition
of commercial-scale cell and gene therapy development and
manufacturing facilities, as well as certain technologies and
equipment from Talaris in Houston, Texas and Louisville, Kentucky.
The acquisition of both locations, combined with NYBCe’s
Comprehensive Cell Solutions (CCS) vast cell sourcing and
collection network, accelerates the delivery of a fully integrated
vein-to-vein cell and gene therapy development and manufacturing
solution for the continental United States (US), capable of serving
the biopharma industry and large hospital systems.
“I am exceptionally pleased with this strategic
expansion of our CCS portfolio,” said Christopher D. Hillyer, MD,
President and Chief Executive Officer at NYBCe, “which now allows
NYBCe to have in-house start-to-finish cell and gene therapy, and
regenerative medicine, development and manufacturing capabilities.
Our new facilities and expert teams are located within key
geographies, with best-in-class GMP manufacturing, and a
close-to-patient transportation network as well as leading academic
medical centers, which will allow us to fast-track lifesaving
therapies to hospital systems.”
Both state-of-the-art facilities offer space for
autologous and allogeneic cell sourcing and collection, expanding
NYBCe’s large collection footprint and broad donor base. The
Louisville, Kentucky facility adds approximately 20,000 sq. ft.
with quality control and Phase 3-fitted GMP manufacturing capacity.
The space provides ISO 7 cleanrooms, vast GMP capacity,
cryopreservation, and storage and warehouse space, a robust digital
chain of identity systems, supported by rigorous testing and
release procedures. The Houston, Texas facility offers another
6,000 sq. ft. of analytical and process development capacity
enhancing NYBCe’s expertise in broad analytical methodologies
across cell types, viral vectors, mRNA, and gene expression
analysis.
“We are delighted to have this portfolio of CMC
assets become a part of CCS,” said Mary Kay Fenton, President and
Interim Chief Executive Officer, Talaris Therapeutics, Inc.
“CCS’ acquisition will improve the process of drug
development and delivery for patients with life-threatening
cancers, as well as severe blood and genetic disorders. We look
forward to bringing on additional talent from the cell and gene
therapy hubs of Houston and Louisville and providing the highest
quality cell and gene therapies for biopharma companies and
hospitals throughout the US,” said Jay Mohr, Executive Vice
President, Chief Business Officer, NYBCe.
About New York Blood Center
Enterprises
Founded in 1964, New York Blood Center Enterprises
(NYBCe) provides blood and stem cell products and related medical
and consultative services. Since inception, NYBCe has been
committed to areas of health and humanitarian causes with a global
lifesaving impact. NYBCe is at the forefront of leading innovative
research in hematology, blood banking, transfusion medicine,
infectious diseases, and cellular therapies. NYBCe has also
advanced numerous groundbreaking innovations in clinical care and
biotechnology with patented disruptive technologies that have been
adopted globally.
About Comprehensive Cell
Solutions
Founded in 2003 as a business unit of New York
Blood Center Enterprises, CCS offers its deep expertise in the
development and manufacture of cell and gene therapies, using its
GMP and GTP facilities. CCS provides a true vein-to-vein solution,
spanning fresh cellular collections and cord blood-derived stem
cells as source material, to cell isolation, manipulation, and
cryopreservation capabilities for preclinical to commercial stage
products. CCS boasts a client roster comprised of the world’s
leading pharmaceutical companies, innovative biotechnology
organizations, and academic medical centers. CCS’ manufacturing
headquarters are in New York City, where it also performs cellular
collections and clinical apheresis. Cell collection suites and
apheresis services are also based in Providence, RI, Kansas City,
MO, and St. Paul, MN.
About Talaris Therapeutics,
Inc.
Talaris Therapeutics, Inc., prior to its announced
merger with Tourmaline Therapeutics, was a late stage, cell therapy
company developing an innovative method of allogeneic hematopoietic
stem cell transplantation (“allo-HSCT”), called Facilitated
Allo-HSCT Therapy.
Contacts
Media:Jonathan
PappasJPappas@lifescicomms.com857-205-4403
Talaris Therapeutics (NASDAQ:TALS)
Historical Stock Chart
From May 2024 to Jun 2024
Talaris Therapeutics (NASDAQ:TALS)
Historical Stock Chart
From Jun 2023 to Jun 2024